Research ArticleOriginal Article
Open Access

Evaluation of early biomarkers of renal dysfunction in diabetic patients

Shrouq F. Al-Hazmi, Hoda G. M. Gad, Aliaa A. Alamoudi, Basmah M. Eldakhakhny, Sarah K. Binmahfooz and Amani M. Alhozali
Saudi Medical Journal July 2020, 41 (7) 690-697; DOI: https://doi.org/10.15537/smj.2020.7.25168

References

  1. ↵
    1. Parchwani D,
    2. Upadhyah A
    (2012) Diabetic nephropathy:Progression and pathophysiology. International Journal of Medical Science and Public Health 1:59.
    OpenUrl
  2. ↵
    1. Ambade V,
    2. Sing P,
    3. Somani BL,
    4. Basanna D
    (2006) Urinary N-acetyl beta glucosaminidase and gamma glutamyl transferase as early markers of diabetic nephropathy. Indian J Clin Biochem 21:142–148.
    OpenUrl
  3. ↵
    1. Lee SY,
    2. Choi ME
    (2015) Urinary biomarkers for early diabetic nephropathy:beyond albuminuria. Pediatr Nephrol 30:1063–1075.
    OpenUrl
  4. ↵
    1. Coles M,
    2. Diercks T,
    3. Muehlenweg B,
    4. Bartsch S,
    5. Zolzer V,
    6. Tschesche H,
    7. et al.
    (1999) The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol 289:139–157.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nickolas TL,
    2. Barasch J,
    3. Devarajan P
    (2008) Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 17:127–132.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Malyszko J,
    2. Malyszko JS,
    3. Bachorzewska-Gajewska H,
    4. Poniatowski B,
    5. Dobrzycki S,
    6. Mysliwiec M
    (2008) Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplantation 86:41.
    OpenUrl
  7. ↵
    1. Nikolov G,
    2. Boncheva M,
    3. Gruev T,
    4. Biljali S,
    5. Stojceva-Taneva O,
    6. Masim-Spasovska E
    (2013) Urinary biomarkers in the early diagnosis of renal damage in diabetes mellitus patients. Scripta Scientifica Medica 45:58.
    OpenUrl
  8. ↵
    1. Bouvet BR,
    2. Paparella CV,
    3. Arriaga SMM,
    4. Monje AL,
    5. Amarilla AM,
    6. Almara AM
    (2014) Evaluation of urinary N-acetyl-beta-D-glucosaminidase as a marker of early renal damage in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol 58:798–801.
    OpenUrl
  9. ↵
    1. Chew JS,
    2. Saleem M,
    3. Florkowski CM,
    4. George PM
    (2008) Cystatin C--a paradigm of evidence based laboratory medicine. Clin Biochem Rev 29:47–62.
    OpenUrlPubMed
  10. ↵
    1. Han WK,
    2. Wagener G,
    3. Zhu Y,
    4. Wang S,
    5. Lee HT
    (2009) Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 4:873–882.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kawanami D,
    2. Matoba K,
    3. Utsunomiya K
    (2016) Dyslipidemia in diabetic nephropathy. Renal Replacement Therapy 2:16.
    OpenUrl
  12. ↵
    1. Decavele A-SC,
    2. Dhondt L,
    3. De Buyzere ML,
    4. Delanghe JR
    (2011) Increased urinary neutrophil gelatinase associated lipocalin in urinary tract infections and leukocyturia. Clin Chem Lab Med 49:999–1003.
    OpenUrlCrossRefPubMed
    1. Cowland JB,
    2. Borregaard N
    (1997) Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 45:17–23.
    OpenUrlCrossRefPubMedWeb of Science
    1. Hemdahl A-L,
    2. Gabrielsen A,
    3. Zhu C,
    4. Eriksson P,
    5. Hedin U,
    6. Kastrup J,
    7. et al.
    (2006) Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 26:136–142.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Wiesli P,
    2. Schwegler B,
    3. Spinas GA,
    4. Schmid C
    (2003) Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta 338:87–90.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Resnick HE,
    2. Foster GL,
    3. Bardsley J,
    4. Ratner RE
    (2006) Achievement of American Diabetes Association Clinical Practice Recommendations Among U.S. Adults With Diabetes 1999-2002:The National Health and Nutrition Examination Survey. Diabetes Care 29:531–537.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease
    (2007) American Journal of Kidney Diseases 49(2 Suppl 2):S12–154.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Wang C,
    2. Li C,
    3. Gong W,
    4. Lou T
    (2013) New urinary biomarkers for diabetic kidney disease. Biomark Res 1:9.
    OpenUrl
  19. ↵
    1. Assal HS,
    2. Tawfeek S,
    3. Rasheed EA,
    4. El-Lebedy D,
    5. Thabet EH
    (2013) Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes 6:CMED. S12633.
    OpenUrl
  20. ↵
    1. Nauta FL,
    2. Boertien WE,
    3. Bakker SJL,
    4. Van Goor H,
    5. Van Oeveren W,
    6. De Jong PE,
    7. et al.
    (2011) Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34:975–981.
    OpenUrlAbstract/FREE Full Text
    1. Wu J,
    2. Shao X,
    3. Lu K,
    4. Zhou J,
    5. Ren M,
    6. Xie X,
    7. et al.
    (2017) Urinary RBP and NGAL Levels are Associated with Nephropathy in Patients with Type 2 Diabetes. Cell Physiol Biochem 42:594–602.
    OpenUrl
  22. ↵
    1. Siddiqi Z,
    2. Karoli R,
    3. Kaul A,
    4. Fatima J,
    5. Varshney S,
    6. Beg MS
    (2017) Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as early markers of diabetic nephropathy. Ann Afr Med 16:101–106.
    OpenUrl
  23. ↵
    1. Zeng X-F,
    2. Lu D-X,
    3. Li J-M,
    4. Tan Y,
    5. Li Z,
    6. Zhou L,
    7. et al.
    (2017) Performance of urinary neutrophil gelatinase-associated lipocalin, clusterin, and cystatin C in predicting diabetic kidney disease and diabetic microalbuminuria:a consecutive cohort study. BMC Nephrol 18:233.
    OpenUrl
  24. ↵
    1. Kaul A,
    2. Behera M,
    3. Rai M,
    4. Mishra P,
    5. Bhaduaria D,
    6. Yadav S,
    7. et al.
    (2018) Neutrophil gelatinase-associated lipocalin:as a predictor of early diabetic nephropathy in type 2 diabetes mellitus. Indian J Nephrol 28:53–60.
    OpenUrl
  25. ↵
    1. Al-Rubeaan K,
    2. Siddiqui K,
    3. Al-Ghonaim MA,
    4. Youssef AM,
    5. Al-Sharqawi AH,
    6. AlNaqeb D
    (2017) Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients. Sci Rep 7:2684.
    OpenUrl
  26. ↵
    1. Kim SS,
    2. Song SH,
    3. Kim IJ,
    4. Yang JY,
    5. Lee JG,
    6. Kwak IS,
    7. et al.
    (2012) Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract 97:251–257.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Chakraborty S,
    2. Kaur S,
    3. Guha S,
    4. Batra SK
    (2012) The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 1826:129–169.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Nielsen SE,
    2. Sugaya T,
    3. Tarnow L,
    4. Lajer M,
    5. Schjoedt KJ,
    6. Astrup AS,
    7. et al.
    (2009) Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 32:1684–1688.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Bouvet BR,
    2. Paparella CV,
    3. Arriaga SMM,
    4. Monje AL,
    5. Amarilla AM,
    6. Almar AM
    (2014) Evaluation of urinary N-acetyl-beta-D-glucosaminidase as a marker of early renal damage in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol 58:798–801.
    OpenUrl
  30. ↵
    1. Kim SR,
    2. Lee Y-h,
    3. Lee S-G,
    4. Kang ES,
    5. Cha B-S,
    6. Kim J-H,
    7. et al.
    (2016) Urinary N-acetyl-d-glucosaminidase, an early marker of diabetic kidney disease, might reflect glucose excursion in patients with type 2 diabetes. Medicine 95:27.
    OpenUrl
  31. ↵
    1. Patel DN,
    2. Kalia K
    (2015) Efficacy of urinary N-acetyl-?-D-glucosaminidase to evaluate early renal tubular damage as a consequence of type 2 diabetes mellitus:a cross-sectional study. Int J Diabetes Dev Ctries 35:449–457.
    OpenUrl
  32. ↵
    1. Mahfouz MH,
    2. Assiri AM,
    3. Mukhtar MH
    (2016) Assessment of neutrophil gelatinase-associated lipocalin (NGAL) and retinol-binding protein 4 (RBP4) in type 2 diabetic patients with nephropathy. Biomark Insights 11:31–40.
    OpenUrl
  33. ↵
    1. Takir M,
    2. Unal AD,
    3. Kostek O,
    4. Bayraktar N,
    5. Demirag NG
    (2016) Cystatin-C and TGF-beta levels in patients with diabetic nephropathy. Nefrologia 36:653–659.
    OpenUrl
  34. ↵
    1. Javanmardi M,
    2. Azadi N-A,
    3. Amini S,
    4. Abdi M
    (2015) Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients:The first experience in Iran. J Res Med Sci 20:571–576.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords